301207 Stock Overview
Engages in the research, development, production, and sale of vaccines in China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Hualan Biological Vaccine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥18.08 |
| 52 Week High | CN¥36.00 |
| 52 Week Low | CN¥15.42 |
| Beta | 0.73 |
| 11 Month Change | -0.17% |
| 3 Month Change | 2.32% |
| 1 Year Change | -46.82% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.42% |
Recent News & Updates
Recent updates
Potential Upside For Hualan Biological Vaccine Inc. (SZSE:301207) Not Without Risk
Jul 25
Hualan Biological Vaccine's (SZSE:301207) Upcoming Dividend Will Be Larger Than Last Year's
Jun 11Revenue Downgrade: Here's What Analysts Forecast For Hualan Biological Vaccine Inc. (SZSE:301207)
Apr 03Hualan Biological Vaccine Inc. Just Missed Revenue By 9.2%: Here's What Analysts Think Will Happen Next
Apr 02Hualan Biological Vaccine Inc.'s (SZSE:301207) Subdued P/E Might Signal An Opportunity
Apr 01An Intrinsic Calculation For Hualan Biological Vaccine Inc. (SZSE:301207) Suggests It's 31% Undervalued
Mar 04Shareholder Returns
| 301207 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 14.6% | 7.4% | 9.6% |
| 1Y | -46.8% | -23.7% | -12.3% |
Return vs Industry: 301207 underperformed the CN Biotechs industry which returned -23.7% over the past year.
Return vs Market: 301207 underperformed the CN Market which returned -12.3% over the past year.
Price Volatility
| 301207 volatility | |
|---|---|
| 301207 Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in CN Market | 8.4% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 301207 has not had significant price volatility in the past 3 months.
Volatility Over Time: 301207's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 770 | Wenjue An | www.hualanbacterin.com |
Hualan Biological Vaccine Inc. engages in the research, development, production, and sale of vaccines in China. It offers influenza virus split vaccines, quadrivalent influenza virus split vaccines, H1N1 influenza virus split vaccines, ACYW135 meningococcal polysaccharide plague vaccines, recombinant hepatitis B vaccines, and group A and C meningococcal polysaccharide vaccines, as well as genetic engineering vaccines for human use. The company was founded in 2005 and is based in Xinxiang, China.
Hualan Biological Vaccine Inc. Fundamentals Summary
| 301207 fundamental statistics | |
|---|---|
| Market cap | CN¥10.83b |
| Earnings (TTM) | CN¥777.02m |
| Revenue (TTM) | CN¥2.30b |
13.9x
P/E Ratio4.7x
P/S RatioIs 301207 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301207 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.30b |
| Cost of Revenue | CN¥392.28m |
| Gross Profit | CN¥1.90b |
| Other Expenses | CN¥1.13b |
| Earnings | CN¥777.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.30 |
| Gross Margin | 82.92% |
| Net Profit Margin | 33.84% |
| Debt/Equity Ratio | 5.1% |
How did 301207 perform over the long term?
See historical performance and comparison